Sanofi to exercise option on third SAFEbody discovery program and sponsor combination clinical trial with muzastotug - ...

Sanofi has agreed to invest up to $25m in Adagene, which will enable the latter to fund its research and development (R&D) ...

Adagene Inc. (NASDAQ:ADAG) saw its shares rise by 6.1% on Tuesday after the biotech firm revealed a strategic investment deal ...

Sanofi has doubled down on its partnership with Adagene, investing $25 million in the biotech, taking up its option on a ...

Adagene’s lead clinical program, ADG126 (muzastotug), is a masked, anti-CTLA-4 SAFEbody that targets a unique epitope of CTLA-4 in regulatory T cells (Tregs) in the tumor microenvironment.

Sino-American antibody company Adagene (Nasdaq: ADAG) has announced a strategic investment and option exercise by Sanofi ...

Sanofi agreed to invest up to $25 million in the clinical-stage biotechnology company. Adagene said it plans to use the proceeds to fund its research and development activities, including clinical ...

Adagene to Present at Jefferies Global Healthcare Conference 2025. SAN DIEGO and SUZHOU, China, May 27, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming ...

Investing.com -- Adagene Inc. (NASDAQ: ADAG) stock surged 6.1% after the antibody-based therapeutics company announced a strategic investment of up to $25 million from Sanofi (EPA: SASY) and the ...

Adagene’s lead clinical program, ADG126 (muzastotug), is a masked, anti-CTLA-4 SAFEbody that targets a unique epitope of CTLA-4 in regulatory T cells (Tregs) in the tumor microenvironment.

American depositary receipts of Adagene rose 15% in premarket trading following an investment from Sanofi. ADRs were trading around $2.24. The stock is down 2% on the year. Sanofi agreed to invest ...